Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ajt.14721 http://scihub22266oqcxt.onion/10.1111/ajt.14721 C6055714!6055714!29509295     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 310.4 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Transplant 2018 ; 18 (7): 1783-9 Nephropedia Template TP {{tp|p=29509295|t=2018. De novo donor?specific antibodies in belatacept?treated vs cyclosporine?treated kidney?transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT?EXT studies |pdf=|usr=}}{{29509295}} gab.com Text De novo donor specific antibodies in belatacept treated vs cyclosporine treated kidney transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT EXT studies JO: Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=29509295 #FOAvip Donor?specific antibodies (DSAs) are associated with an increased risk of antibody?mediated rejection and graft failure. In BENEFIT and BENEFIT?EXT, kidney?transplant recipients were randomized to receive belatacept more intense (MI)?based, belatacept less intense (LI)?based, or cyclosporine?based immunosuppression for up to 7 years (84 months). The presence/absence of HLA?specific antibodies was determined at baseline, at months 6, 12, 24, 36, 48, 60, and 84, and at the time of clinically suspected episodes of acute rejection, using solid?phase flow?cytometry screening. Samples from anti?HLA?positive patients were further tested with a single?antigen bead assay to determine antibody specificities, presence/absence of DSAs, and mean fluorescence intensity (MFI) of any DSAs present. In BENEFIT, de novo DSAs developed in 1.4%, 3.5%, and 12.1% of belatacept MI?treated, belatacept LI?treated, and cyclosporine?treated patients, respectively. The corresponding values in BENEFIT?EXT were 3.8%, 1.1%, and 11.2%. Per Kaplan?Meier analysis, de novo DSA incidence was significantly lower in belatacept?treated vs cyclosporine?treated patients over 7 years in both studies (P < .01). In patients who developed de novo DSAs, belatacept?based immunosuppression was associated with numerically lower MFI vs cyclosporine?based immunosuppression. Although derived post hoc, these data suggest that belatacept?based immunosuppression suppresses de novo DSA development more effectively than cyclosporine?based immunosuppression. Twit Text FOAVip De novo donor specific antibodies in belatacept treated vs cyclosporine treated kidney transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT EXT studies ????Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=29509295 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29509295 #FOAvip English Wikipedia <ref>{{Cite pmid|29509295}}</ref> De novo donor?specific antibodies in belatacept?treated vs cyclosporine?treated kidney?transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT?EXT studies #MMPMID29509295 Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier?Kriesche H; Larsen CP Am J Transplant 2018[Jul]; 18 (7): 1783-9 PMID29509295show ga Donor?specific antibodies (DSAs) are associated with an increased risk of antibody?mediated rejection and graft failure. In BENEFIT and BENEFIT?EXT, kidney?transplant recipients were randomized to receive belatacept more intense (MI)?based, belatacept less intense (LI)?based, or cyclosporine?based immunosuppression for up to 7 years (84 months). The presence/absence of HLA?specific antibodies was determined at baseline, at months 6, 12, 24, 36, 48, 60, and 84, and at the time of clinically suspected episodes of acute rejection, using solid?phase flow?cytometry screening. Samples from anti?HLA?positive patients were further tested with a single?antigen bead assay to determine antibody specificities, presence/absence of DSAs, and mean fluorescence intensity (MFI) of any DSAs present. In BENEFIT, de novo DSAs developed in 1.4%, 3.5%, and 12.1% of belatacept MI?treated, belatacept LI?treated, and cyclosporine?treated patients, respectively. The corresponding values in BENEFIT?EXT were 3.8%, 1.1%, and 11.2%. Per Kaplan?Meier analysis, de novo DSA incidence was significantly lower in belatacept?treated vs cyclosporine?treated patients over 7 years in both studies (P < .01). In patients who developed de novo DSAs, belatacept?based immunosuppression was associated with numerically lower MFI vs cyclosporine?based immunosuppression. Although derived post hoc, these data suggest that belatacept?based immunosuppression suppresses de novo DSA development more effectively than cyclosporine?based immunosuppression. äDe novo donor?specific antibodies in belatacept?treated vs cyclosporin(epmc).pdf DeepDyve Pubget Overpricing